Free Trial

LLA.L,0P0001T9GN,0 (LLA) Competitors

LLA vs. IDHC, DXRX, AGL, YGEN, ABDX, PRM, GDR, VRCI, GENI, and DMTR

Should you be buying LLA.L,0P0001T9GN,0 stock or one of its competitors? The main competitors of LLA.L,0P0001T9GN,0 include Integrated Diagnostics (IDHC), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), Verici Dx (VRCI), GENinCode (GENI), and Deepmatter Group (DMTR). These companies are all part of the "diagnostics & research" industry.

LLA.L,0P0001T9GN,0 vs. Its Competitors

LLA.L,0P0001T9GN,0 (LON:LLA) and Integrated Diagnostics (LON:IDHC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Integrated Diagnostics has a net margin of 17.21% compared to LLA.L,0P0001T9GN,0's net margin of 0.00%. Integrated Diagnostics' return on equity of 30.45% beat LLA.L,0P0001T9GN,0's return on equity.

Company Net Margins Return on Equity Return on Assets
LLA.L,0P0001T9GN,0N/A -48.59% -27.28%
Integrated Diagnostics 17.21%30.45%9.69%

Integrated Diagnostics has higher revenue and earnings than LLA.L,0P0001T9GN,0. LLA.L,0P0001T9GN,0 is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LLA.L,0P0001T9GN,0N/AN/A-£4.47M-£0.12N/A
Integrated Diagnostics£23.29T0.00£4.01T£0.0312.34

LLA.L,0P0001T9GN,0 has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, Integrated Diagnostics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Integrated Diagnostics received 56 more outperform votes than LLA.L,0P0001T9GN,0 when rated by MarketBeat users.

CompanyUnderperformOutperform
LLA.L,0P0001T9GN,0N/AN/A
Integrated DiagnosticsOutperform Votes
56
65.12%
Underperform Votes
30
34.88%

In the previous week, LLA.L,0P0001T9GN,0's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
LLA.L,0P0001T9GN,0 Neutral
Integrated Diagnostics Neutral

5.4% of LLA.L,0P0001T9GN,0 shares are held by institutional investors. Comparatively, 43.0% of Integrated Diagnostics shares are held by institutional investors. 34.0% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Integrated Diagnostics beats LLA.L,0P0001T9GN,0 on 11 of the 11 factors compared between the two stocks.

Get LLA.L,0P0001T9GN,0 News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLA vs. The Competition

MetricLLA.L,0P0001T9GN,0Diagnostics & Research IndustryMedical SectorLON Exchange
Market CapN/A£731.82M£5.61B£2.93B
Dividend YieldN/A5.44%5.28%4.90%
P/E Ratio-25.002.0927.14125.70
Price / SalesN/A480.02411.84243,028.65
Price / CashN/A11.4238.2528.07
Price / BookN/A2.877.064.71
Net Income-£4.47M£308.37B£3.23B£5.91B

LLA.L,0P0001T9GN,0 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLA
LLA.L,0P0001T9GN,0
N/AN/AN/AN/A£0.00N/A-25.0015Gap Down
High Trading Volume
IDHC
Integrated Diagnostics
N/AGBX 0.36
flat
N/A+0.6%£10.60B£23.29T13.386,692
DXRX
Diaceutics
2.5948 of 5 stars
GBX 132
+2.3%
GBX 160
+21.2%
-1.2%£111.40M£26.08M-39.15151
AGL
ANGLE
2.4252 of 5 stars
GBX 8
flat
GBX 40
+400.0%
-51.7%£25.78M£2.44M-1.18650
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 6.83
-2.4%
N/A-39.5%£13.23M£3.84M-16.6184Gap Down
PRM
Proteome Sciences
N/AGBX 3.62
+13.5%
N/A-16.0%£10.69M£10.88B-2.62240Gap Down
GDR
genedrive
N/AGBX 1.37
-5.9%
N/A-10.0%£7.75M£1.50M-0.3843Gap Down
VRCI
Verici Dx
N/AGBX 1.68
+3.4%
N/A-82.1%£5.10M£5.91M-0.9719Gap Down
GENI
GENinCode
N/AGBX 2.38
+8.2%
N/A-66.5%£4.22M£2.67M-0.692,300Gap Down
High Trading Volume
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down

Related Companies and Tools


This page (LON:LLA) was last updated on 6/13/2025 by MarketBeat.com Staff
From Our Partners